Covisint (COVS) Posts Q4 Loss of 17c/Share

Covisint (NASDAQ: COVS) reported Q4 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $17 million versus the consensus estimate of $24.66 million.

For earnings history and earnings-related data on Covisint (COVS) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data
• Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c